罗沙司他治疗慢性肾脏病伴地中海贫血的临床经验  

Clinical experience of roxadustat in the treatment of chronic kidney disease with thalassemia

作　　者：敖广宇 李晶 唐园源 陈民[1] Ao Guangyu;Li Jing;Tang Yuanyuan;Chen Min(Department of Nephrology,Chengdu First People's Hospital,Chengdu 610095,China)

机构地区：[1]成都市第一人民医院肾脏内科,成都610095

出　　处：《中华肾脏病杂志》2024年第12期968-971,共4页Chinese Journal of Nephrology

基　　金：成都市医学科研课题(2023383);四川省医学会肾病专项课题(2024SY18)。

摘　　要：慢性肾脏病(chronic kidney disease,CKD)患者同时合并肾性贫血和地中海贫血时致病机制复杂,可合并多种铁代谢紊乱情况,是临床上导致患者疗效不佳的原因之一。该文报告了5例CKD 3~4期合并地中海贫血患者应用罗沙司他治疗的病例。治疗结果显示,所有患者的贫血程度较前均有所改善,且未观察到铁过载的发生。这些经验表明,罗沙司他能有效提升肾性贫血伴地中海贫血患者的血红蛋白水平,同时发生铁过载的风险较低。Chronic kidney disease(CKD)patients with concurrent renal anemia and thalassemia present complex pathogenesis involving various iron metabolism disorders,which are among the key factors contributing to suboptimal therapeutic outcomes.This paper reports the clinical experience of treating five CKD stage 3-4 patients with thalassemia using roxadustat.The treatment outcomes demonstrated that all patients experienced significant improvements in anemia,and no cases of iron overload were observed throughout the follow-up period.These findings suggest that roxadustat effectively increases hemoglobin levels in patients with renal anemia and thalassemia while maintaining a low risk of iron overload,providing a potential therapeutic option for these challenging cases.

关 键 词：肾功能不全 慢性 地中海贫血 铁代谢障碍 肾性贫血 罗沙司他 

分 类 号：R692[医药卫生—泌尿科学] R556.61[医药卫生—外科学]